Cambridge, MA
Vedere is developing cutting-edge gene therapy products to restore functional vision to patients who have suffered vision loss from Inherited Retinal Degenerations (IRDs), as well as other causes of both genetic and non-genetic vision loss. While the vast majority of ocular gene therapies only limit the rate of inevitable vision loss, we aim to restore lost vision regardless of a patientโs underlying genetics or their stage of disease.
vederebio.comThese are collections Vedere Bio is a part of. Click on the collection name to view similar companies.
Series A
$77,000,000
Series A
$21,000,000
0 out of 5 stars
Based on 0 reviews
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Vedere Bio.